Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MGEN

Miragen Therapeutics (MGEN) Stock Price, News & Analysis

Miragen Therapeutics logo

About Miragen Therapeutics Stock (NASDAQ:MGEN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$12.53
$13.47
50-Day Range
$14.34
$23.01
52-Week Range
$4.66
$34.05
Volume
1.09 million shs
Average Volume
134,027 shs
Market Capitalization
$49.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Remove Ads
Receive MGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MGEN Stock News Headlines

Why Elon Musk Is Investigating Fort Knox
With gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulate more of the precious metal, the timing couldn't be more critical. If the gold reserves in Fort Knox are found to be less than officially reported, we could see gold prices skyrocket virtually overnight.
Viridian Therapeutics Inc (VRDN)
See More Headlines

MGEN Stock Analysis - Frequently Asked Questions

Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its quarterly earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative trailing twelve-month return on equity of 141.66% and a negative net margin of 1,393.50%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia Oyj (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE).

Company Calendar

Last Earnings
11/10/2020
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:MGEN
Fax
N/A
Employees
45
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-41,870,000.00
Net Margins
-1,393.50%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.46 million
Price / Cash Flow
N/A
Book Value
$6.78 per share
Price / Book
1.85

Miscellaneous

Free Float
N/A
Market Cap
$49.08 million
Optionable
Not Optionable
Beta
1.66
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:MGEN) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners